124 related articles for article (PubMed ID: 2412024)
1. Effect of ketanserin on hemodynamics, plasma-catecholamine concentrations, and serotonin uptake by platelets in volunteers and patients with congestive heart failure.
Grobecker H; Gessler I; Delius W; Dominiak P; Kees F
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S102-4. PubMed ID: 2412024
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.
Majid PA; Morris WM; Sole MJ
Can J Cardiol; 1987 Mar; 3(2):70-4. PubMed ID: 3567710
[TBL] [Abstract][Full Text] [Related]
3. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
van de Water A; Wouters L; Xhonneux R; Reneman S
Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
[TBL] [Abstract][Full Text] [Related]
5. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.
Fagard R; Cattaert A; Lijnen P; Staessen J; Vanhees L; Moerman E; Amery A
Clin Sci (Lond); 1984 Jan; 66(1):17-25. PubMed ID: 6690191
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravenous ketanserin on plasma catecholamines and renin activity in normal volunteers.
Reimann IW; Ratge D; Wisser H; Klotz U
Eur J Clin Pharmacol; 1985; 28(3):273-7. PubMed ID: 3159583
[TBL] [Abstract][Full Text] [Related]
7. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin.
Breuer J; Meschig R; Breuer HW; Arnold G
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S64-6. PubMed ID: 2412062
[TBL] [Abstract][Full Text] [Related]
8. Serotonin-induced vasoconstriction in the perfused canine femoral artery can be blocked in vivo by ketanserin.
Meschig R; Breuer J; Arnold G
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S56-9. PubMed ID: 2412060
[TBL] [Abstract][Full Text] [Related]
9. Role of serotonin in patients with acute respiratory failure.
Huval WV; Lelcuk S; Shepro D; Hechtman HB
Ann Surg; 1984 Aug; 200(2):166-72. PubMed ID: 6547816
[TBL] [Abstract][Full Text] [Related]
10. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
De Clerck F; Xhonneux B
Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
[TBL] [Abstract][Full Text] [Related]
11. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
[TBL] [Abstract][Full Text] [Related]
12. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
De Clerck F; Xhonneux B
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5-hydroxytryptamine blockade with ketanserin on myocardial uptake of epinephrine and norepinephrine in patients with congestive heart failure.
Majid PA; Sole MJ
J Clin Pharmacol; 1987 Sep; 27(9):661-5. PubMed ID: 3680595
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and blood gas responses to ketanserin in canine pulmonary edema induced by oleic acid.
Koyama S; Kiyono S; Kayaba K; Kimura M; Nishizawa M
Anesthesiology; 1985 Apr; 62(4):457-61. PubMed ID: 3157333
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease.
Zannad F; Voisin P; Pointel JP; Schmitt C; Freitag B; Stoltz JF
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S32-4. PubMed ID: 2412053
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5HT-induced shape change and 5HT uptake in rat and human platelets.
Lampugnani MG; de Gaetano G
Biochem Pharmacol; 1982 Sep; 31(18):3000-2. PubMed ID: 7138588
[No Abstract] [Full Text] [Related]
17. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
Wenting GJ; Man in 't Veld AJ; Woittiez AJ; Boomsma F; Schalekamp MA
Br Med J (Clin Res Ed); 1982 Feb; 284(6315):537-9. PubMed ID: 6800533
[TBL] [Abstract][Full Text] [Related]
18. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
Buczko W; Gambino MC; De Gaetano G
Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.
Bolt GR; Saxena PR
Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161
[TBL] [Abstract][Full Text] [Related]
20. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
